SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SAFS (Safescience, Inc.) formerly IGGI. Hot Potential -- Ignore unavailable to you. Want to Upgrade?

To: Mr Zone who wrote (92)6/29/1999 11:56:00 PM
From: Biopyro  Read Replies (1) | Respond to of 110
 
Since Daniel seems to be a SAFS expert, can you please explain me if PSA levels are a good predictor of treatment outcome for prostate cancer? What kind of conclusions can we draw from the recently reported Phase I/II study with GC-590? Is the FDA likely to recognize this surrogate marker as an clinical endpoint in later stage efficacy trials?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News